Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
GLP-1 Drugs and Skin Cancer Risk
A new Dermatologic Surgery paper links semaglutide and tirzepatide to lower skin cancer rates in patients with obesity, but the abstract isn't public yet.
Semax/Selank blend: the dosing math gap
Semax/Selank blend dosing math fails for one reason: the vial never states how much of each peptide it actually contains.
Tirzepatide and Atrial Fibrillation Risk
A new meta-analysis of 10 trials found no significant link between tirzepatide and atrial fibrillation, though the data remain thin and uncertain.
Testing Tirzepatide After Gastric Bypass
A Vanderbilt pilot trial called GRABS is testing tirzepatide in patients whose obesity persists after gastric bypass surgery.
Can you drink alcohol on tirzepatide?
The tirzepatide label lists no alcohol interaction and no trial has tested the combination. Here is where the two sets of risks actually overlap.
IGF-1, HGH, and tesamorelin: what to know
IGF-1 of 159 ng/mL means little without a baseline and an age-matched range. This article explains what the number means and how tesamorelin differs from HGH.
Incretin malnutrition review explained
A new review of tirzepatide, semaglutide and related trials raises nutrition questions without proving common clinical malnutrition.
What Medicare's GLP-1 bridge may cost
CMS has disclosed Medicare's $50 GLP-1 copay and a manufacturer net price, but not a total taxpayer cost estimate.
Mwyngil's non-GLP-1 obesity approach
Mwyngil is pursuing GPR75 and NLRP3 pathways for obesity. The targets are interesting, but the program remains preclinical.
How to read an oral GLP-1 script tracker
A new tracker follows oral Wegovy and Foundayo prescriptions. Here is what script growth can show, and what it cannot.
PT-141 microdosing: what the label says
Daily sub-label PT-141 schedules sit outside the Vyleesi label and well below the lowest dose ever taken into a published controlled trial.
T-BEAT Japan: design, not results
The T-BEAT paper describes a Japanese tirzepatide and oral semaglutide study, but reports baseline data rather than treatment outcomes.